Patents by Inventor Waldemar Pfrengle

Waldemar Pfrengle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
    Patent number: 9751855
    Abstract: The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 5, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Thorsten Pachur, Thomas Nicola, Adil Duran
  • Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
    Patent number: 9499546
    Abstract: The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: November 22, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Thorsten Pachur, Thomas Nicola, Adil Duran
  • Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
    Patent number: 9212183
    Abstract: The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, processes for making these novel salts, and pharmaceutical compositions comprising such novel salts. The invention also relates to the use of these novel salts in the treatment of type 2 diabetes.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: December 15, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Waldemar Pfrengle
  • Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
    Patent number: 9199998
    Abstract: The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: December 1, 2015
    Assignee: Boehringer Ingelheim Internatioal GmbH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
    Patent number: 8962636
    Abstract: The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV(DPP-IV).
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 24, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • 9-[4-(3-chloro-2-fluoro-phenylamino-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof
    Patent number: 8906931
    Abstract: The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Guenther Huchler, Markus Ostermeier, Peter Sieger
  • Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
    Patent number: 8883805
    Abstract: The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: November 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Thorsten Pachur, Thomas Nicola, Adil Duran
  • Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
    Patent number: 8883800
    Abstract: The present invention relates to substituted quinazolines of formula (I): wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • Salt forms of a xanthine compound
    Patent number: 8865729
    Abstract: The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, a DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2, diabetes, as well as their production.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: October 21, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Waldemar Pfrengle
  • SUBSTITUTED QUINAZOLINES, THE PREPARATION THEREOF AND THE USE THEREOF IN PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140228283
    Abstract: The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-W (DPP-IV).
    Type: Application
    Filed: July 13, 2012
    Publication date: August 14, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
    Patent number: 8686148
    Abstract: The invention relates to a process for preparing new tiotropium salts, these new tiotropium salts as such, pharmaceutical formulations containing them and their use for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: April 1, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Banholzer, Waldemar Pfrengle, Peter Sieger
  • 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
    Patent number: 8637530
    Abstract: The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Peter Sieger
  • ACID ADDITION SALTS OF THE 2-[2-[[(4-METHOXY-2,6-DIMETHYLPHENYL)SULFONYL]-(METHYL)AMINO]ETHOXY]-N-METHYL-N-[3-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL] ACETAMIDE AND THE USE THEREOF AS BRADYKININ B1 RECEPTORANTAGONISTS
    Publication number: 20130289049
    Abstract: The present invention relates to the new acid addition salts AB of the following free base of formula A or the enantiomer thereof with a physiologically acceptable acid B which is selected from among hydrochloric acid, fumaric acid and tartaric acid, as well as the polymorphs, hydrates and solvates thereof.
    Type: Application
    Filed: August 4, 2011
    Publication date: October 31, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Pachur, Waldemar Pfrengle, Manfred Birk, Juergen Schnaubelt, Ulrike Werthmann
  • Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
    Patent number: 8541450
    Abstract: The invention relates to enantiomerically pure 3-(phthalimido)piperidines and processes for preparing enantiomerically pure 3-(phthalimido)piperidines.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: September 24, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Thorsten Pachur
  • Process for the stereoselective preparation of bicyclic heterocycles
    Patent number: 8263768
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of general formula (I) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: September 11, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Ostermeier, Stefan Braith, Juergen Daeubler, Guenther Huchler, Waldemar Pfrengle
  • Process for making certain compounds having B1 antagonistic activity
    Patent number: 8207335
    Abstract: The present invention relates to a method of preparing compounds of general formula I wherein m, n, R1 and R2 are defined as mentioned hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Adil Duran, Markus Frank, Waldemar Pfrengle, Juergen Schnaubelt
  • SALT FORMS OF ORGANIC COMPOUND
    Publication number: 20120129874
    Abstract: The present invention relates to novel salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, a DPP-4 inhibitor and their use in pharmaceutical compositions useful in the treatment of type 2, diabetes, as well as their production.
    Type: Application
    Filed: December 22, 2009
    Publication date: May 24, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Sieger, Waldemar Pfrengle
  • PROCESS FOR THE STEREOSELECTIVE PREPARATION OF BICYCLIC HETEROCYCLES
    Publication number: 20120116080
    Abstract: The present invention relates to a process for the stereoselective preparation of compounds of general formula (I) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
    Type: Application
    Filed: July 23, 2009
    Publication date: May 10, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Markus Ostermeier, Stefan Braith, Juergen Daeubler, Guenther Huchler, Waldemar Pfrengle
  • 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
    Patent number: 8106060
    Abstract: The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.
    Type: Grant
    Filed: July 30, 2006
    Date of Patent: January 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Peter Sieger
  • Method for producing scopine esters
    Patent number: 8101763
    Abstract: The invention relates to a novel method for producing scopine esters of the general formula (1), wherein X—, R, R1, R2, R3, R4, R3?, R4?, R6 and R6? can have the meanings indicated in the claims and in the description.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: January 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Werner Rall, Joerg Brandenburg, Rolf Herter